The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Biohaven Pharma (BHVN) has filed a mixed shelf registration statement with the SEC, granting the company the option to raise capital by selling various types of securities over time. The filing encompasses potential offerings of common shares, preferred shares, debt securities, warrants, and other investment units. While the registration is active, the total size of the offering was not disclosed in the official filing. This strategic move follows the company's successful completion of enrollment for its Phase 2 obesity study, marking a significant clinical milestone. The filing is intended to provide Biohaven with the financial flexibility necessary to fund future operations or clinical developments. Market reaction was positive, with the stock trading up 5.30% following the announcement.
Sign in to access this content
Sign In